Amgen, Inc. (NASDAQ:AMGN) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $205.13 and last traded at $204.51, with a volume of 64679 shares trading hands. The stock had previously closed at $203.37.

AMGN has been the topic of a number of research reports. Cann reissued a “buy” rating on shares of Amgen in a report on Friday, June 8th. Citigroup increased their price objective on Amgen from $188.00 to $200.00 and gave the company a “neutral” rating in a report on Monday, July 30th. Robert W. Baird increased their price objective on Amgen from $165.00 to $179.00 and gave the company a “neutral” rating in a report on Monday, July 30th. Mizuho reissued a “buy” rating and issued a $200.00 price objective on shares of Amgen in a report on Friday, June 22nd. Finally, Goldman Sachs Group reissued a “buy” rating and issued a $228.00 price objective on shares of Amgen in a report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $203.03.

The firm has a market capitalization of $130.97 billion, a P/E ratio of 16.25, a PEG ratio of 1.97 and a beta of 1.39. The company has a debt-to-equity ratio of 2.03, a current ratio of 3.39 and a quick ratio of 3.12.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, July 26th. The medical research company reported $3.83 EPS for the quarter, topping the consensus estimate of $3.52 by $0.31. The firm had revenue of $6.06 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. Amgen’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period last year, the company earned $3.27 earnings per share. research analysts predict that Amgen, Inc. will post 13.96 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 7th. Investors of record on Friday, August 17th were issued a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 2.58%. The ex-dividend date of this dividend was Thursday, August 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.

In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $195.71, for a total transaction of $298,457.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.19% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Pillar Pacific Capital Management LLC boosted its position in Amgen by 0.5% during the second quarter. Pillar Pacific Capital Management LLC now owns 56,671 shares of the medical research company’s stock worth $10,461,000 after purchasing an additional 254 shares in the last quarter. Fairfield Bush & CO. boosted its position in Amgen by 0.8% during the second quarter. Fairfield Bush & CO. now owns 33,934 shares of the medical research company’s stock worth $6,264,000 after purchasing an additional 260 shares in the last quarter. Advisors Capital Management LLC boosted its position in Amgen by 5.8% during the second quarter. Advisors Capital Management LLC now owns 4,737 shares of the medical research company’s stock worth $874,000 after purchasing an additional 261 shares in the last quarter. Highland Capital Management LLC boosted its position in Amgen by 1.0% during the second quarter. Highland Capital Management LLC now owns 27,457 shares of the medical research company’s stock worth $5,068,000 after purchasing an additional 262 shares in the last quarter. Finally, Mutual Advisors LLC boosted its position in Amgen by 5.8% during the second quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock worth $889,000 after purchasing an additional 265 shares in the last quarter. 82.44% of the stock is currently owned by hedge funds and other institutional investors.

About Amgen (NASDAQ:AMGN)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Read More: Short Selling – Explanation For Shorting Stocks

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.